GlassScriptPhysician profile
Irena Pleskova
NPI 1639129026
$13,301.74
in general payments reported to CMS, 2019-2025
52 companies · $2,791 in 2025
The $2,791 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $840 · 2021: $1,660 · 2022: $2,038 · 2023: $2,047 · 2024: $2,952 · 2025: $2,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,790.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,388.28 | 2019-2025 | |
| Amgen INC. | $891.79 | 2019-2025 | Evenity, Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $731.36 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $718.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $685.90 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $661.02 | 2019-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $617.21 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $467.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $465.19 | 2019-2025 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $437.59 | 2023-2025 | Nuzyra, Xhance |
| Amarin Pharma, INC. | $420.14 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $410.47 | 2020-2024 | Linzess |
| Allergan, INC. | $295.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $295.29 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $292.51 | 2024-2025 | Zenpep |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irena Pleskova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.